NCT01733992View on ClinicalTrials.gov

A Safety, Tolerability and Pharmacokinetics Study of R932348 Eye Drops in Patients With Dry Eye Disease

PHASE1CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

November 30, 2012

Primary Completion Date

February 28, 2013

Study Completion Date

February 28, 2013

Conditions
Keratoconjunctivitis Sicca
Interventions
DRUG

R348 Ophthalmic Solution, 0.2%

R348 Ophthalmic Solution, 0.2% single and multiple ascending dose

DRUG

R348 Ophthalmic Solution, 0.5%

R348 Ophthalmic Solution, 0.5%, single and multiple ascending dose

DRUG

R348 Ophthalmic Solution, 1.0%

R348 Ophthalmic Solution, 1.0%, single and multiple ascending dose

DRUG

Placebo

Placebo, single and multiple ascending dose

Trial Locations (1)

01810

Andover Eye Associates, Andover

Sponsors
All Listed Sponsors
lead

Rigel Pharmaceuticals

INDUSTRY